Alterity Therapeutics Limited ATHE NASDAQ · Healthcare · Australia
$1.52 -8.43% -$0.14
Summary
65 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: $37.3M against $193.5K.
- It beat profit estimates 7 times in the last 8 quarters.
What to watch
- It passes only 1 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapIs it growing?
Yes, fastRevenue (AUD)
Diluted EPS (AUD)
- Analyst estimate
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
Over the last 12 months it made a loss of $23.4M.
Profitability in detailIs it financially healthy?
YesIt holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 4
- Hold 4
- Sell 0
Today's price within the analysts' price targets
The average target of $8 is 426% above today's price. 50% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.